BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Accenture
Citi
Harvard Business School
Chubb
Queensland Health
Dow
Johnson and Johnson
Novartis
Covington

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,540,665

« Back to Dashboard

Which drugs does patent 8,540,665 protect, and when does it expire?

Patent 8,540,665 protects ZINGO and is included in one NDA.

This patent has four patent family members in four countries.
Summary for Patent: 8,540,665
Title:Particle cassettes and processes therefor
Abstract: An article for use in manufacturing particle cassettes comprising one or more single pieces of membrane having a plurality of gas flow passages bonded thereto. The article allows convenient manufacture of particle cassettes. Two such articles may be employed to provide a finished particle cassette and a production line in which a plurality of gas flow passages are conveyed on a single membrane is disclosed.
Inventor(s): Bates; Nigel Robert (The Oxford Science Park, GB), Price; Philip Thomas (The Oxford Science Park, GB)
Assignee: Powder Pharmaceuticals Inc. (Hong Kong, HK)
Application Number:12/612,586
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 8,540,665

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007 RX No No ➤ Subscribe ➤ Subscribe ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,540,665

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0708758May 04, 2007

Non-Orange Book US Patents Family Members for Patent 8,540,665

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,044,546 Particle cassettes and processes therefor ➤ Subscribe
9,358,338 Particle cassettes and processes therefor ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,540,665

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 066425 ➤ Subscribe
United Kingdom 0708758 ➤ Subscribe
Taiwan 200916139 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2008135719 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
US Army
Cipla
Moodys
Cerilliant
Medtronic
Covington
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot